Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ACIU
#3396
AC Immune SA - Common Stock
2.4
1
USD
-0.02%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.63%
Monthly Change
-11.72%
6 month change
-27.19%
Year Change
-29.74%
Previous Close
2.4
5
Open
2.4
3
Low
2.3
9
High
2.4
4
Markets
US Stock Market
Healthcare
Biotechnology
ACIU
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
Current
Key stats
Total common shares outstanding
71.94 M
83.48 M
83.62 M
99.2 M
100.41 M
101.74 M
101.74 M
Valuation ratios
Enterprise value
371.91 M
413.22 M
184.8 M
465.24 M
271.11 M
319.47 M
248.25 M
Price to earnings ratio
—
—
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
—
—
Price to book ratio
—
—
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
—
—
—
—
—
—
—
Return on equity %
—
—
—
—
—
—
—
Return on invested capital %
—
—
—
—
—
—
—
Gross margin %
—
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
—
—
—
—
—
—
—
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
—
—
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
—
—
Working capital per share
—
—
—
—
—
—
—
Book value per share
—
—
—
—
—
—
—
News
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know
PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal
Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation
Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%
Novo's Wegovy Pill Shows Weight Loss After Switching From Injections
Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study
NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk
uniQure Plunges on Additional Data From Huntington's Disease Study
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026